Arvinas Inc
$ 7.42
-4.13%
05 Jun - close price
- Market Cap 478,747,000 USD
- Current Price $ 7.42
- High / Low $ 7.81 / 7.40
- Stock P/E N/A
- Book Value 6.00
- EPS -3.18
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.42 %
- 52 Week High 14.51
- 52 Week Low 6.05
About
Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins. The company is headquartered in New Haven, Connecticut.
Analyst Target Price
$15.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-02-24 | 2025-11-05 | 2025-08-06 | 2025-05-01 | 2025-02-11 | 2024-10-30 | 2024-07-30 | 2024-05-07 | 2024-02-27 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -0.9 | -1.1 | -0.48 | -0.84 | 1.14 | -0.63 | -0.68 | -0.49 | -0.97 | -2.53 | -1.18 | -1.25 |
| Estimated EPS | -0.9641 | -0.57 | -0.74 | -0.89 | -0.97 | -0.96 | -0.87 | -0.59 | -1.38 | -1.27 | -1.58 | -1.61 |
| Surprise | 0.0641 | -0.53 | 0.26 | 0.05 | 2.11 | 0.33 | 0.19 | 0.1 | 0.41 | -1.26 | 0.4 | 0.36 |
| Surprise Percentage | 6.6487% | -92.9825% | 35.1351% | 5.618% | 217.5258% | 34.375% | 21.8391% | 16.9492% | 29.7101% | -99.2126% | 25.3165% | 22.3602% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.33 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARVN
2026-06-05 22:41:00
Arvinas is strategically refining its pipeline focus, emphasizing internal investment in neurological and oncology programs while seeking partnerships for other assets after achieving the first PROTAC degrader approval with Veppanu. The company is advancing several key programs, including ARV-102 for Parkinson's and PSP, ARV-027 for Kennedy's disease, and ARV-393 for hematologic disorders, with plans for upcoming trial data and phase advancements. Arvinas aims to differentiate its therapies and leverage its strong balance sheet for targeted internal development.
2026-06-05 16:10:16
Arvinas (NASDAQ:ARVN) is refining its development strategy, prioritizing internal investment in neurological and oncology programs while seeking partners for other assets, especially after the first PROTAC degrader approval with Veppanu. The company is focusing on key pipeline assets like ARV-102 for neurological diseases and ARV-027 for a rare disease, expecting significant trial data and milestones this year and next, underscoring a disciplined approach to capital allocation. Arvinas aims to differentiate its therapies, moving beyond a broad platform approach to concentrate on programs with strong potential for clinical impact and market opportunity.
2026-06-04 12:39:41
Arvinas, a clinical-stage biotechnology company, has partnered with The Michael J. Fox Foundation's LRRK2 Cohort Consortium (LITE) and the Parkinson's Progression Markers Initiative (PPMI). This collaboration aims to advance protein degrader research for Parkinson's disease, leveraging Arvinas' proprietary platform and the Foundation's extensive clinical data and biological samples. The goal is to refine PROTAC protein degrader development and better understand LRRK2 mutations to inform new treatments for LRRK2-linked Parkinson's.
2026-06-04 11:39:41
Arvinas (Nasdaq: ARVN) has joined the Michael J. Fox Foundation's LRRK2 Investigative Therapeutics Exchange (LITE) and Parkinson’s Precision Medicine Initiative (PPMI) programs. This collaboration aims to accelerate the development of ARV-102, an investigational PROTAC targeting LRRK2 for neurodegenerative diseases like Parkinson's and progressive supranuclear palsy (PSP). The partnership leverages shared data, biomarker infrastructure, and expert networks to enhance the understanding of LRRK2 biology and inform clinical development strategies for ARV-102.
2026-06-04 11:39:41
Arvinas, Inc. has joined The Michael J. Fox Foundation's LRRK2 Investigative Therapeutics Exchange (LITE) program and Parkinson’s Precision Medicine Initiative (PPMI). This collaboration aims to advance ARV-102, Arvinas’ investigational targeted protein degrader for neurodegenerative diseases like Parkinson's and PSP, through enhanced data generation and understanding of LRRK2 biology. The initiatives foster collaborative research to accelerate the development of better and more personalized treatments for Parkinson's disease.
2026-06-03 14:10:25
Stephens & Co. has reiterated an Overweight rating for Arvinas Inc (ARVN), maintaining a price target of $18.00, suggesting a positive outlook and significant upside potential from its current trading price of $8.00, which GuruFocus deems 29.9% undervalued. The company's GF Score™ of 67 indicates moderate long-term return potential, with strong financial strength and momentum, despite challenges in profitability and valuation. Investors are advised to consider these factors, along with mixed insider activity, before making investment decisions.
